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Abstract

Caplan and colleagues (2015) present a strong argument for using alternative trial designs for experimental
treatments for Ebola virus disease (EVD). This argument is, of course, not new. There is a significant body of
work in the philosophy of medicine that highlights the moral authority given to randomized controlled trials
(RCTs) and the fact that RCTs are often chosen not because these are needed but because people simply do
not recognize that they can get evidence that is just as useful from other trial designs (Kerridge 2010).
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Impure politics and pure science: efficacious Ebola
medications are only a palliation and not a cure for structural
disadvantage
Degeling C1, Johnson J, Mayes C. (2015)
Caplan and colleagues (2015) present a strong argument for using alternative trial designs
for experimental treatments for Ebola virus disease (EVD). This argument is, of course, not
new. There is a significant body of work in the philosophy of medicine which highlights the
moral authority given to RCTs and the fact that RCTs are often chosen not because they are
needed but because people simply do not recognise that they can get evidence that is just as
useful from other trial designs (Kerridge 2010).
The popularity of RCTs as a research methodology is supported by positivist assumptions
that well-conducted RCTs permit experimenters to make strong causal claims and
conclusions because this trial design uniquely controls for confounding factors. RCTs do
generally provide robust evidence, yet as the philosopher of science John Worrall (2007)
demonstrates, randomisation, as a methodological principle, is not a sufficient condition to
guarantee that the trial outcome will not be adversely influenced by uncontrolled or
unknown factors. What this means is that RCTs are not necessarily epistemically secure or
even always epistemically superior. But, like other trial designs, the data generated by RCTs
needs to be interpreted in light of other sources and forms of evidence. This raises concerns
that the epistemic and moral authority accorded to RCTs can mandate inappropriate and
ineffective interventions, and divert attention and resources away from other ways of
addressing problems.
RCTs are designed to establish the efficacy of interventions, not their effectiveness. Efficacy
captures what happens in ideal circumstances – RCTs tell us what will happen in a
population of patients given a treatment under specific sets of controlled conditions. RCTs
do not necessarily provide a solid base for extrapolating or generalising what might happen
when different types of individuals are given a treatment under different conditions
(Cartwright 2011). For policy and practice – and especially at a time of pressing need – we do
not need to know that one therapy works better than others (the standard of care (SOC) and
/or other experimental agents) under specific sets of controlled conditions. What we really
need to know is that the intervention will be effective where it is needed most (Cartwright
2011). RCTs are not necessarily the “gold standard” but merely a standard trial design in
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which important considerations such as affordability, sustainability and public acceptability
remain unaddressed. This is undoubtedly relevant to arguments regarding the conduct of
RCTs in West Africa as it suggests not only that randomisation of participants in drug trials in
this setting is morally suspect because of the vulnerability of participants, the nature of the
disease and the lack of capacity and resource scarcity of the setting – but also because
assumptions about the epistemic and ethical benefits of RCTs are questionable; especially if
the goal of the research is to choose the most effective therapy – the one that is most
appropriate to the socio-cultural, economic and political conditions in which it is likely to be
used.
Caplan and colleagues (2015) are right to point out that, epistemologically speaking, RCTs
are not needed and that sufficient evidence about the efficacy of new Ebola therapies can
and should be obtained from other sources. However it is our contention that current
debates about the scientific purity of different trial designs are a distraction from the goal of
developing effective interventions for EVD. This is because the purpose of this research [or
the ‘job’ as described in the target article’s title] is not unproblematic and should be
subjected to ethical scrutiny. It is significant that arguments about different trial designs for
potential Ebola therapies point to the importance of accommodating local conditions and
resource settings. Caplan and colleagues (2015) are careful to limit the frame of their
inquiry to research ethics. But if the social instability and resource scarcity of the setting
where the drug trial is to be conducted are significant epistemic and ethical concerns, it is
arguable that the underlying structural conditions should not be treated as a ‘natural state’
that policymakers and researchers must navigate. Rather, these structural conditions
themselves warrant deeper consideration (Hooker et al. 2014).
Infectious diseases such as Ebola, have, historically, been understood and approached in two
ways: as matters of contamination and as matters of configuration (Rosenberg 1992). From
the perspective of contamination – disease is the transfer and progress of infection between
and within individuals. In the case of the current Ebola outbreak, it seems that the index
case was a two year-old boy infected from eating bush-meat (flying fox) sourced from a
market in Guéckédou, in south-eastern Guinea. Yet even as contact exposure, hostpathogen interactions and clinical interventions determine the disease state of individuals,
these interactions take place in a social and material environment that can be configured in
ways that enhance or inhibit the risk of infection and disease pathogenicity. Of this the field
epidemiologists Daniel Bausch and Lara Schwarz (2014, e3056) note:
Ebola virus outbreaks typically constitute yet another health and economic
burden to Africa's most disadvantaged populations. … The effect of a stalled
economy and government is 3-fold. First, poverty drives people to expand their
range of activities to stay alive, plunging deeper into the forest to expand the
geographic as well as species range of hunted game and to find wood to make
charcoal and deeper into mines to extract minerals, enhancing their risk of
exposure to Ebola virus and other zoonotic pathogens in these remote corners.
Then, the situation is compounded when the unlucky infected person presents
to an impoverished and neglected healthcare facility where a supply of gloves,
clean needles, and disinfectants is not a given, leaving patients and healthcare
workers alike vulnerable to nosocomial transmission.
The cross-species transmissibility and spread of emerging infectious diseases such as EVD
arises from changes in land use, and the intensification of trade, travel and/or animal
husbandry practices (Wallace et al. 2014). The way that society is configured then exposes
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specific populations to a higher or lower risk of infection and enables greater or lesser access
to effective healthcare.
Over the past 40 years many West Africa nations have undergone a process of ‘dedevelopment’. The implementation of structural-adjustment programs (SAPs) in exchange
for World Bank and International Monetary Fund loans re-configured the conditions of
infection (Jones 2011). While SAPs promised economic growth via global trade, they also led
to the erosion of much of the local public infrastructure needed to prevent and control an
infectious disease outbreak. Analyses of the unprecedented nature of the current outbreak
EVD tend to focus on cultural burial practices or lack of drugs. Yet SAPs, civil war, political
instability, corruption, neglect, mass refugee migrations and deforestation have
undoubtedly played a decisive role in creating the conditions and amplifying the risks of
infection (Bausch and Schwarz 2014).
Despite significant re-configuration of the social and material environment, the
contamination view of infectious disease dominates ethical thinking about responses to EVD
- valorising individualised technological solutions and diverting attention away from the
upstream socio-ecological causes and structural drivers of incidence. Drug trials for EVD that
are not integrated with local measures which seek to address differences in people’s
capacities, preferences, cultural commitments and socio-economic and environmental
circumstances are ultimately more likely to produce ineffective interventions while also
entrenching global health inequities.
If the proposed solutions become ever more technological, isolationist and consumerist in
orientation, then existing structures, systems and settings are increasingly likely to be seen
as natural states, and, thereby, not amenable to reform. The development of an effective
therapy for EVD is only part of ‘the job’ that needs to be completed. Prioritising studies that
aim to test pharmaceutical efficacy rather than develop effective interventions that can be
sourced and managed locally amounts to a program of research that further embeds then
medicalizes the consequences of environmental degradation, poverty and structural
disadvantage. Interventions being tested for outbreaks of infectious disease in the
developing world need to be affordable, readily accessible by those who need them and
appropriate to local conditions. If Western interests continue to trump local interests we
should ask: whose health is being prioritized; which public and which good are we seeking to
protect? (Scoones and Forster 2009)
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